Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preference for subcutaneous versus intravenous atezolizumab in NSCLC
2021-004067-28Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoint: Participant preference for subcutaneous vs intravenous atezolizumab. Started Oct 2021; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-004067-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004067-28.